Feasibility of estimation of brain volume and 2-deoxy-2-(18)F-fluoro-D-glucose metabolism using a novel automated image analysis method: application in Alzheimer's disease.

The development of clinically-applicable quantitative methods for the analysis of brain fluorine-18 fluoro desoxyglucose-positron emission tomography ((18)F-FDG-PET) images is a major area of research in many neurologic diseases, particularly Alzheimer's disease (AD). Region of interest visualization, evaluation, and image registration (ROVER) is a novel commercially-available software package which provides automated partial volume corrected measures of volume and glucose uptake from (18)F-FDG PET data. We performed a pilot study of ROVER analysis of brain (18)F-FDG PET images for the first time in a small cohort of patients with AD and controls. Brain (18)F-FDG-PET and volumetric magnetic resonance imaging (MRI) were performed on 14 AD patients and 18 age-matched controls. Images were subjected to ROVER analysis, and voxel-based analysis using SPM5. Volumes by ROVER were 35% lower than MRI volumes in AD patients (as hypometabolic regions were excluded in ROVER-derived volume measurement ) while average ROVER- and MRI-derived cortical volumes were nearly identical in control population. Whole brain volumes when ROVER-derived and whole brain metabolic volumetric products (MVP) were significantly lower in AD and accurately distinguished AD patients from controls (Area Under the Curve (AUC) of Receiver Operator Characteristic (ROC) curves 0.89 and 0.86, respectively). This diagnostic accuracy was similar to voxel-based analyses. Analysis by ROVER of (18)F-FDG-PET images provides a unique index of metabolically-active brain volume, and can accurately distinguish between AD patients and controls as a proof of concept. In conclusion, our findings suggest that ROVER may serve as a useful quantitative adjunct to visual or regional assessment and aid analysis of whole-brain metabolism in AD and other neurologic and psychiatric diseases.

[1]  Janet S. Reddin,et al.  Direct comparison of fluorodeoxyglucose positron emission tomography and arterial spin labeling magnetic resonance imaging in Alzheimer's disease , 2012, Alzheimer's & Dementia.

[2]  F Hofheinz,et al.  Automatic volume delineation in oncological PET , 2011, Nuklearmedizin.

[3]  Cindee M. Madison,et al.  Associations between cognitive, functional, and FDG-PET measures of decline in AD and MCI , 2011, Neurobiology of Aging.

[4]  Abass Alavi,et al.  Feasibility and performance of novel software to quantify metabolically active volumes and 3D partial volume corrected SUV and metabolic volumetric products of spinal bone marrow metastases on 18F-FDG-PET/CT. , 2011, Hellenic journal of nuclear medicine.

[5]  Cindee M. Madison,et al.  Comparing predictors of conversion and decline in mild cognitive impairment , 2010, Neurology.

[6]  James Robert Brašić,et al.  In Vivo Imaging of Amyloid Deposition in Alzheimer Disease Using the Radioligand 18F-AV-45 (Flobetapir F 18) , 2010, Journal of Nuclear Medicine.

[7]  W. Jagust,et al.  The Alzheimer's Disease Neuroimaging Initiative positron emission tomography core , 2010, Alzheimer's & Dementia.

[8]  F. Hofheinz,et al.  Feasibility and utility of ROVER software for 3D quantitative image analysis of FDG-PET in patients with diffuse large B-cell lymphoma (DLBCL) , 2009 .

[9]  H. Rusinek,et al.  Regional analysis of FDG and PIB-PET images in normal aging, mild cognitive impairment, and Alzheimer’s disease , 2008, European Journal of Nuclear Medicine and Molecular Imaging.

[10]  J B Poline,et al.  Direct voxel-based comparison between grey matter hypometabolism and atrophy in Alzheimer's disease. , 2007, Brain : a journal of neurology.

[11]  Henry Rusinek,et al.  Quantitation, regional vulnerability, and kinetic modeling of brain glucose metabolism in mild Alzheimer’s disease , 2007, European Journal of Nuclear Medicine and Molecular Imaging.

[12]  J. Morris,et al.  The Uniform Data Set (UDS): Clinical and Cognitive Variables and Descriptive Data From Alzheimer Disease Centers , 2006, Alzheimer disease and associated disorders.

[13]  A. Convit,et al.  Reduced hippocampal metabolism in MCI and AD , 2005, Neurology.

[14]  L. Mosconi,et al.  Brain glucose metabolism in the early and specific diagnosis of Alzheimer’s disease , 2005, European Journal of Nuclear Medicine and Molecular Imaging.

[15]  K. Ishii,et al.  Comparison of gray matter and metabolic reduction in mild Alzheimer’s disease using FDG-PET and voxel-based morphometric MR studies , 2005, European Journal of Nuclear Medicine and Molecular Imaging.

[16]  W. Klunk,et al.  Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B , 2004, Annals of neurology.

[17]  S. H. Kim,et al.  Thyrotoxic autoimmune encephalopathy: a repeat positron emission tomography study , 2003, Journal of neurology, neurosurgery, and psychiatry.

[18]  et al.,et al.  Discrimination between Alzheimer Dementia and Controls by Automated Analysis of Multicenter FDG PET , 2002, NeuroImage.

[19]  J. Udupa,et al.  Estimation of tumor volume with fuzzy-connectedness segmentation of MR images. , 2002, AJNR. American journal of neuroradiology.

[20]  G. Alexander,et al.  Positron emission tomography in evaluation of dementia: Regional brain metabolism and long-term outcome. , 2001, JAMA.

[21]  Jayaram K. Udupa,et al.  Multiprotocol MR Image Segmentation in Multiple Sclerosis , 2001 .

[22]  Jayaram K. Udupa,et al.  Multiprotocol MR image segmentation in multiple sclerosis: experience with over 1000 studies , 2000, Medical Imaging: Image Processing.

[23]  Christian Degueldre,et al.  Voxel‐based analysis of confounding effects of age and dementia severity on cerebral metabolism in Alzheimer's disease , 2000, Human brain mapping.

[24]  Karl J. Friston,et al.  Rapid Assessment of Regional Cerebral Metabolic Abnormalities in Single Subjects with Quantitative and Nonquantitative [18F]FDG PET: A Clinical Validation of Statistical Parametric Mapping , 1999, NeuroImage.

[25]  Santanu Banerjee Original article , 1998, Indian journal of otolaryngology and head and neck surgery : official publication of the Association of Otolaryngologists of India.

[26]  A. Alavi,et al.  Quantitative analysis of PET and MRI data in normal aging and Alzheimer's disease: atrophy weighted total brain metabolism and absolute whole brain metabolism as reliable discriminators. , 1993, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[27]  A. Alavi,et al.  Regional cerebral glucose metabolism in late-life depression and Alzheimer disease: a preliminary positron emission tomography study. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[28]  M J de Leon,et al.  Topography of cross-sectional and longitudinal glucose metabolic deficits in Alzheimer's disease. Pathophysiologic implications. , 1992, Archives of neurology.

[29]  A. Alavi,et al.  Regional brain function in schizophrenia. I. A positron emission tomography study. , 1987, Archives of general psychiatry.